Rapid reduction in HIV viral load in late pregnancy with raltegravir: A case report

10Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The use of raltegravir (RAL) is not preferred to prevent perinatal transmission in pregnancy due to lack of safety and pharmacokinetic data in this population. Data have been limited to few case reports of patients who present for treatment late in pregnancy, have multidrug resistance, or have poor adherence, requiring an additional class such as an integrase inhibitor to further lower viral load. This case report describes and supports the initiation of RAL in very late pregnancy (week 33) to rapidly decrease viral load and successfully prevent perinatal transmission. By increasing the efficacy and safety data of RAL use in pregnancy, we believe this report can help provide some guidance on the management of complex cases. © The Author(s) 2013.

Cite

CITATION STYLE

APA

Cha, A., Shaikh, R., Williams, S., & Berkowitz, L. L. (2013). Rapid reduction in HIV viral load in late pregnancy with raltegravir: A case report. Journal of the International Association of Providers of AIDS Care, 12(5), 312–314. https://doi.org/10.1177/2325957413488176

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free